Webinars


Hepatitis E

52.1 - Hepatitis E: An Emerging Virus in Solid-Organ Transplantation

Presenter: Nassim, Kamar, Toulouse, France
Authors: Nassim Kamar


Overview:

Hepatitis E virus (HEV) infection is a worldwide disease. An improved understanding of the natural history of HEV infection has been achieved within the last decade. It is an underdiagnosed disease HEV infection is usually an acute self-limiting disease, but causes chronic infection with rapidly progressive cirrhosis in adult and pediatric organ-transplant-patients. HEV can also cause extra-hepatic manifestations, such as neurological symptoms and kidney injury. Reducing immunosuppression in transplant-patients can lead to HEV clearance in one-third of patients with chronic hepatitis. The use of anti-viral therapy such as pegylated-interferon and ribavirin, have been found to be efficient at treating HEV infection.


Biography:

Nassim Kamar (MD, PhD) is a Professor of Nephrology. He is in charge of the organ Transplant Unit at the Department of Nephrology and Organ Transplantation, Toulouse University Hospital, France. He is a Member of the Council of the International Transplant Infectious Disease Society. His particular interests are viral infection, particularly hepatitis E virus, hepatitis C virus, and cytomegalovirus infections that develop after solid organ transplantation, as well as immunosuppressive therapy in heart, liver, kidney, and kidney-pancreas transplant patients.


You must be logged in to view recordings

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi